x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012253
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MAP7 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MAP7 |
| UniProt No. | Q14244 |
| Gene ID | 9053 |
| Gene Description | MAP7 is a member of the Microtubule-Associated Proteins that regulates the stability and function of the cytoskeleton in cells. MAP7 facilitates the transport of organelles, such as mitochondria and lysosomes, via recruitment of kinesin-1. This role of MAP7 in organelle transport occurs in neuronal and non-neuronal cells, including Drosophila oocytes, and in S2 cells and mammalian muscle cells. In addition to promoting organelle transport via kinesin-1 recruitment, MAP7 also contributes to the morphogenesis of axons that is domain-specific, whereas the full-length MAP7 promotes branch maturation, N- and P- domains are responsible for branch formation, and the C-terminal kinesin-interacting domain contributes to the axonal growth. MAP7 and the paralog MAP7D1 directly interact with disheveled, an effector of the Wnt5a β-catenin-independent pathway, regulating the microtubule remodeling, cell migration, and cell adhesion in HeLa cells. MAP7 is considered a biomarker in a model to treat multiple sclerosis based on the tolerogenic dendritic cells induced by vitamin D3. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
